Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Apollomics Inc. APLM

5 fiscal years on record · USD · FY2024 reported · SEC filings only
$0
$-53.9M
$-28.8M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 0.00
Revenue, FY2024 · full 5-year series below
Revenue $M Net income $M
FY2024 · Revenue 0.0 · Net income -53.9
-100M-200M
202020232024
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
ROE

Not applicable: equity was zero or negative in this period, so return on equity has no meaning.

Three returns, three denominators.
Return on capital employedNot available: we don't have a clean operating profit figure for this period.

Each USD of equity lost 234 cents this year.

Cash & shareholders

·
returned in FY2024 · dividends + net buybacks
Free cash flow $M
FY2024 · FCF -28.8
-20M-40M
202020222024

Total assetsUSD 13.1M
CashUSD 9.8M
Gross debtUSD 0.00
Net debtUSD -9.8M
Current ratio1.39×

Net debt stands at -201% of equity.

The 5-year record

5 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
APLM, 5-year financial record
Metric 20242023202220212020
Revenue $B0.00.00.00.00.0
Operating income $B◌◌0.0◌◌
EBITDA $B◌◌◌◌◌
Income tax $B0.00.00.00.0−0.0
Net income $B−0.1−0.2−0.2−0.1−0.1
Free cash flow $B−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−52.80−231.99−844.95−3.37−0.21
Dividend / sh $◌◌◌◌◌
Payout % — not applicable: no dividend—————
ROE %−233.7————

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 1 failure in 15 reconciliationsAUDITED

Reconciled in 4 of the 5 fiscal years we could check. 28 checks were skipped: the balance sheet is not tagged before 2021. 13 checks were skipped: EPS is not tagged before 2020.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency1 failure
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code E9
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2020

Share this section

Download image